These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

883 related articles for article (PubMed ID: 27626691)

  • 1. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy.
    Gray PN; Vuong H; Tsai P; Lu HM; Mu W; Hsuan V; Hoo J; Shah S; Uyeda L; Fox S; Patel H; Janicek M; Brown S; Dobrea L; Wagman L; Plimack E; Mehra R; Golemis EA; Bilusic M; Zibelman M; Elliott A
    Oncotarget; 2016 Oct; 7(42):68206-68228. PubMed ID: 27626691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
    Cheng DT; Mitchell TN; Zehir A; Shah RH; Benayed R; Syed A; Chandramohan R; Liu ZY; Won HH; Scott SN; Brannon AR; O'Reilly C; Sadowska J; Casanova J; Yannes A; Hechtman JF; Yao J; Song W; Ross DS; Oultache A; Dogan S; Borsu L; Hameed M; Nafa K; Arcila ME; Ladanyi M; Berger MF
    J Mol Diagn; 2015 May; 17(3):251-64. PubMed ID: 25801821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing.
    Cheng DT; Prasad M; Chekaluk Y; Benayed R; Sadowska J; Zehir A; Syed A; Wang YE; Somar J; Li Y; Yelskaya Z; Wong D; Robson ME; Offit K; Berger MF; Nafa K; Ladanyi M; Zhang L
    BMC Med Genomics; 2017 May; 10(1):33. PubMed ID: 28526081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.
    de Leng WW; Gadellaa-van Hooijdonk CG; Barendregt-Smouter FA; Koudijs MJ; Nijman I; Hinrichs JW; Cuppen E; van Lieshout S; Loberg RD; de Jonge M; Voest EE; de Weger RA; Steeghs N; Langenberg MH; Sleijfer S; Willems SM; Lolkema MP
    PLoS One; 2016; 11(2):e0149405. PubMed ID: 26919633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Treatment-Focused Tumor Sequencing to Screen for Germline Cancer Predisposition.
    Lau TTY; May CM; Sefid Dashti ZJ; Swanson L; Starks ER; Parker JDK; Moore RA; Tucker T; Bosdet I; Young SS; Santos JL; Compton K; Heidary N; Hoang L; Schrader KA; Sun S; Kwon JS; Tinker AV; Karsan A
    J Mol Diagn; 2021 Sep; 23(9):1145-1158. PubMed ID: 34197922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.
    Hovelson DH; McDaniel AS; Cani AK; Johnson B; Rhodes K; Williams PD; Bandla S; Bien G; Choppa P; Hyland F; Gottimukkala R; Liu G; Manivannan M; Schageman J; Ballesteros-Villagrana E; Grasso CS; Quist MJ; Yadati V; Amin A; Siddiqui J; Betz BL; Knudsen KE; Cooney KA; Feng FY; Roh MH; Nelson PS; Liu CJ; Beer DG; Wyngaard P; Chinnaiyan AM; Sadis S; Rhodes DR; Tomlins SA
    Neoplasia; 2015 Apr; 17(4):385-99. PubMed ID: 25925381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors.
    Ananda G; Mockus S; Lundquist M; Spotlow V; Simons A; Mitchell T; Stafford G; Philip V; Stearns T; Srivastava A; Barter M; Rowe L; Malcolm J; Bult C; Karuturi RK; Rasmussen K; Hinerfeld D
    Exp Mol Pathol; 2015 Feb; 98(1):106-12. PubMed ID: 25562415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
    Zakrzewski F; Gieldon L; Rump A; Seifert M; Grützmann K; Krüger A; Loos S; Zeugner S; Hackmann K; Porrmann J; Wagner J; Kast K; Wimberger P; Baretton G; Schröck E; Aust D; Klink B
    BMC Cancer; 2019 Apr; 19(1):396. PubMed ID: 31029168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TumorNext-Lynch-MMR: a comprehensive next generation sequencing assay for the detection of germline and somatic mutations in genes associated with mismatch repair deficiency and Lynch syndrome.
    Gray PN; Tsai P; Chen D; Wu S; Hoo J; Mu W; Li B; Vuong H; Lu HM; Batth N; Willett S; Uyeda L; Shah S; Gau CL; Umali M; Espenschied C; Janicek M; Brown S; Margileth D; Dobrea L; Wagman L; Rana H; Hall MJ; Ross T; Terdiman J; Cullinane C; Ries S; Totten E; Elliott AM
    Oncotarget; 2018 Apr; 9(29):20304-20322. PubMed ID: 29755653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality control material for the detection of somatic mutations in fixed clinical specimens by next-generation sequencing.
    Dumur CI; Almenara JA; Powers CN; Ferreira-Gonzalez A
    Diagn Pathol; 2015 Sep; 10():169. PubMed ID: 26376646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the Oncomine
    Williams HL; Walsh K; Diamond A; Oniscu A; Deans ZC
    Virchows Arch; 2018 Oct; 473(4):489-503. PubMed ID: 30105577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amplicon-Based Targeted Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Tissue.
    Strengman E; Barendrecht-Smouter FAS; de Voijs C; de Vree P; Nijman IJ; de Leng WWJ
    Methods Mol Biol; 2019; 1908():1-17. PubMed ID: 30649717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal.
    Sun JX; He Y; Sanford E; Montesion M; Frampton GM; Vignot S; Soria JC; Ross JS; Miller VA; Stephens PJ; Lipson D; Yelensky R
    PLoS Comput Biol; 2018 Feb; 14(2):e1005965. PubMed ID: 29415044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer.
    Garcia EP; Minkovsky A; Jia Y; Ducar MD; Shivdasani P; Gong X; Ligon AH; Sholl LM; Kuo FC; MacConaill LE; Lindeman NI; Dong F
    Arch Pathol Lab Med; 2017 Jun; 141(6):751-758. PubMed ID: 28557599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors.
    Luthra R; Patel KP; Routbort MJ; Broaddus RR; Yau J; Simien C; Chen W; Hatfield DZ; Medeiros LJ; Singh RR
    J Mol Diagn; 2017 Mar; 19(2):255-264. PubMed ID: 28017569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens.
    Pritchard CC; Salipante SJ; Koehler K; Smith C; Scroggins S; Wood B; Wu D; Lee MK; Dintzis S; Adey A; Liu Y; Eaton KD; Martins R; Stricker K; Margolin KA; Hoffman N; Churpek JE; Tait JF; King MC; Walsh T
    J Mol Diagn; 2014 Jan; 16(1):56-67. PubMed ID: 24189654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy and reproducibility of somatic point mutation calling in clinical-type targeted sequencing data.
    Karimnezhad A; Palidwor GA; Thavorn K; Stewart DJ; Campbell PA; Lo B; Perkins TJ
    BMC Med Genomics; 2020 Oct; 13(1):156. PubMed ID: 33059707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients.
    Lee A; Kang J; Lee H; Lee YS; Choi YJ; Lee KH; Nistala GJ; Scafe CR; Choi J; Yoo J; Han M D E; Kim Y; Kim M
    Pathol Res Pract; 2019 Nov; 215(11):152595. PubMed ID: 31570282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-laboratory validation of the OncoScan® FFPE Assay, a multiplex tool for whole genome tumour profiling.
    Foster JM; Oumie A; Togneri FS; Vasques FR; Hau D; Taylor M; Tinkler-Hundal E; Southward K; Medlow P; McGreeghan-Crosby K; Halfpenny I; McMullan DJ; Quirke P; Keating KE; Griffiths M; Spink KG; Brew F
    BMC Med Genomics; 2015 Feb; 8():5. PubMed ID: 25889064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A method to reduce ancestry related germline false positives in tumor only somatic variant calling.
    Halperin RF; Carpten JD; Manojlovic Z; Aldrich J; Keats J; Byron S; Liang WS; Russell M; Enriquez D; Claasen A; Cherni I; Awuah B; Oppong J; Wicha MS; Newman LA; Jaigge E; Kim S; Craig DW
    BMC Med Genomics; 2017 Oct; 10(1):61. PubMed ID: 29052513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.